Skip to main content

Table 3 Univariate analyses of factors associated with bone metastasis in 157 HCC patients

From: Serum lnc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients

Variable Bone metastasis
HR (95% CI) P
Age (≤56 versus > 56 years) 0.725(0.286–1.840) 0.499
Gender (male versus female) 1.864(0.539–6.445) 0.325
HBsAg (negative versus positive) 1.849(0.425–8.047) 0.412
HCV-Ab (negative versus positive) 1.707(0.227–12.838) 0.603
AFP, ng/mL (≤ 20 versus > 20) 1.612(0.574–4.526) 0.364
ALT,U/L (≤ 40 versus > 40) 0.255(0.034–1.915) 0.184
γ-GT,U/L (≤ 50 versus > 50) 1.032(0.400–2.662) 0.949
Liver cirrhosis (no versus yes) 4.662(0.620–35.039) 0.135
Child-Pugh score (A versus B) 1.155(0.153–8.697) 0.889
Tumor differentiation (I–II versus III–IV) 1.504(0.597–3.789) 0.387
Tumor size, cm (≤ 5 versus > 5) 0.657(0.216–1.996) 0.458
Tumor number (single versus multiple) 0.963(0.373–2.486) 0.937
Tumor encapsulation (complete versus none) 1.079(0.426–2.737) 0.872
Vascular invasion (no versus yes) 10.054(3.572–28.302) < 0.001
BCLC stage (0-A versus B-C) 7.193(2.361–21.919) 0.001
Lnc34a (low versus high) 5.385(1.558–18.612) 0.008
  1. HCC hepatocellular carcinoma, HBsAg hepatitis B surface antigen, HCV-Ab hepatitis C virus antibody, AFP a-fetoprotein, ALT alanine aminotransferase, γ-GT γ-glutamyl transferase, BCLC-stage Barcelona Clinic Liver Cancer-stage